Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.36 |
| ▸ | CCNC | P24863 | 9/20 | 0.36 |
| ▸ | CDK8 | P49336 | 9/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108721 | 0.93 | HSD11B1 (0.39) | ADRB2HSD11B1CCNCCDK8OPRM1 | |
| SCHEMBL1108712 | 0.91 | HSD11B1 (0.43) | HSD11B1NR1I2 | |
| SCHEMBL1108728 | 0.85 | OPRD1 (0.43) | HSD11B1CYP3A4 | |
| SCHEMBL1108706 | 0.85 | HSD11B1 (0.44) | HSD11B1NR1I2 | |
| Hydrochloric Acid SCHEMBL1100547 | 0.84 | HSD11B1 (0.43) | HSD11B1NR1I2CYP3A4 | |
| SCHEMBL1108707 | 0.80 | CYP3A4 (0.37) | ADRB2HSD11B1CCNCCDK8NR1I2 | |
| SCHEMBL1108704 | 0.80 | CYP3A4 (0.37) | ADRB2HSD11B1OPRM1NR1I2CYP3A4 | |
| SCHEMBL1108714 | 0.79 | MEN1 (0.45) | HSD11B1OPRM1NR1I2 | |
| SCHEMBL1108715 | 0.77 | CYP3A4 (0.39) | HSD11B1CYP3A4 | |
| SCHEMBL1108703 | 0.77 | CYP3A4 (0.37) | OPRM1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | HSD11B1, HSD17B1, HSD17B3 | ADRB2 1307/4885HSD11B1 1/4885CCNC 4581/4885 |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | GPR119, CYP11B2, CYP11B1 | ADRB2 880/4885HSD11B1 41/4885CCNC 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.